Paloma Partners Management Co lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 56.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,821 shares of the medical instruments supplier’s stock after selling 36,760 shares during the period. Paloma Partners Management Co’s holdings in Becton, Dickinson and were worth $5,287,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rockland Trust Co. acquired a new position in Becton, Dickinson and during the first quarter valued at about $307,000. Wells Fargo & Company MN raised its position in Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock valued at $602,246,000 after buying an additional 39,362 shares during the period. AMG National Trust Bank raised its position in Becton, Dickinson and by 4.2% in the first quarter. AMG National Trust Bank now owns 9,880 shares of the medical instruments supplier’s stock valued at $1,813,000 after buying an additional 401 shares during the period. Integrated Wealth Management raised its position in Becton, Dickinson and by 3.4% in the first quarter. Integrated Wealth Management now owns 5,444 shares of the medical instruments supplier’s stock valued at $999,000 after buying an additional 181 shares during the period. Finally, Nationwide Fund Advisors raised its position in Becton, Dickinson and by 64.2% in the first quarter. Nationwide Fund Advisors now owns 96,582 shares of the medical instruments supplier’s stock valued at $17,717,000 after buying an additional 37,752 shares during the period. 75.71% of the stock is owned by institutional investors and hedge funds.

Shares of Becton, Dickinson and Company (BDX) traded up 0.9235% during mid-day trading on Friday, reaching $200.0506. 291,062 shares of the company’s stock traded hands. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63. The firm has a 50 day moving average price of $198.75 and a 200-day moving average price of $187.49. The stock has a market cap of $45.52 billion, a PE ratio of 57.9353 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.35 EPS. On average, analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 1.47%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s payout ratio is presently 83.43%.

ILLEGAL ACTIVITY WARNING: “Becton, Dickinson and Company (BDX) Shares Sold by Paloma Partners Management Co” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-shares-sold-by-paloma-partners-management-co/1475619.html.

BDX has been the subject of several recent research reports. Zacks Investment Research lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Evercore ISI raised shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $186.00 to $200.00 in a research report on Monday, April 24th. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their price target for the stock from $210.00 to $180.00 in a research report on Friday, June 30th. Bank of America Corporation reissued a “buy” rating and issued a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $177.00 price target on shares of Becton, Dickinson and in a research report on Thursday, April 13th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $195.79.

In other news, VP Jeffrey S. Sherman sold 28,765 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the completion of the transaction, the vice president now directly owns 70,821 shares in the company, valued at approximately $13,171,289.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.